Table 3.
Comparison of CMB Burdens Among Different Disease Stages
| Variable | Mutation Carriers at Preclinical Stage (n=10) | Symptomatic Carriers With Duration <5 y (n=22) | Symptomatic Carriers With Duration ≥5 y (n=17) | Fisher Exact Test or ANOVA |
|---|---|---|---|---|
| Age, y | 53.0 (39.0–77.0) | 65.5 (36.0–78.0) | 63.0 (41.0–77.0) | P=0.379 |
| Men | 2 (20.0) | 15 (68.2) | 11 (64.7) | P=0.039 |
| Hypertension | 2 (20.0) | 10 (45.5) | 11 (64.7) | P=0.084 |
| Diabetes mellitus | 1 (10.0) | 3 (13.6) | 2 (11.8) | P=1.000 |
| Dyslipidemia | 2 (20.0) | 8 (36.4) | 8 (47.1) | P=0.376 |
| Cigarette smoking | 1 (10.0) | 9 (40.9) | 5 (29.4) | P=0.246 |
| Presence of CMBs | 4 (40.0) | 17 (77.3) | 15 (88.2) | P=0.028 |
| Overall CMB counts | 0 (0–8) | 15 (0–203) | 43 (0–286) | a P trend=0.009 |
| Overall CMB volume ratios, % | 0.00 (0.00–0.01) | 0.01 (0.00–0.16) | 0.03 (0.00–0.20) | a P trend=0.004 |
Data are given as number (percentage) or median (range). CMB indicates cerebral microbleed.
a
P trend was obtained from multivariate linear regression with adjustment of age, sex, and hypertension.